Hong Kong researchers conduct clinical trials for Alzheimer’s surgical procedure

Researchers at the Chinese University of Hong Kong (CUHK) are conducting clinical trials for a surgical procedure aimed at treating Alzheimer’s disease. The procedure involves an operation to drain an abnormal accumulation of two proteins in the brain—tau and myeloid—which are known to damage brain cells and contribute to cognitive decline.

While a similar method was pioneered in Hangzhou in 2018, mainland health authorities have banned its unregulated use in hospitals due to safety and effectiveness concerns. The CUHK team is conducting their trials under strict scientific controls following approval from a joint CUHK-Hospital Authority clinical research ethics committee. So far, four patients have been recruited for the study.

Beyond surgical interventions, medical experts emphasize that early diagnosis is vital for managing the disease. Identifying Alzheimer’s in its nascent stages allows for more effective treatment strategies, participation in clinical trials for cutting-edge therapies, and the implementation of comprehensive care plans that can improve the quality of life for both patients and caregivers.